Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 40Neoplasms 5Colorectal Neoplasms 5Neoplasm Metastasis 3Resectable Pancreatic Cancer 2Rectal Neoplasms 2Carcinoma, Hepatocellular 2Adenocarcinoma 2Urachal cancer 1Stomach Neoplasms 1Pancreatic Ductal Adenocarcinoma (PDAC) 1Pancreatic Cancer Metastatic 1Pancreatic Adenocarcinoma 1Neoplasms, Basal Cell 1Locally Advanced Pancreatic Adenocarcinoma 1Localized Pancreatic Adenocarcinoma 1Gastrointestinal Neoplasms 1Gastroesophageal Adenocarcinoma 1Gastro-enteropancreatic neuroendocrine tumor 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Islet Cell 1Borderline Resectable Pancreatic Cancer 1Biliary Tract Neoplasms 1Ampullary Adenocarcinoma 1

Interventions

Gemcitabine 11Albumin-Bound Paclitaxel 7Taxes 5130-nm albumin-bound paclitaxel 4Radiotherapy, Intensity-Modulated 3Radiotherapy 3Fluorouracil 3dehydroftorafur 2Oxaliplatin 2Losartan 2Leucovorin 2Irinotecan 2Cisplatin 2niraparib 1irinotecan sucrosofate 1folfirinox 1durvalumab 1X-Rays 1Surgical Procedures, Operative 1Standard of Care 1Specimen Handling 1S 1 (combination) 1Resistance Training 1Radiotherapy, Image-Guided 1Radiosurgery 1Radiation 1Panitumumab 1Pancreaticoduodenectomy 1Optical Imaging 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Pancreatic Adenocarcinoma × folfirinox × Clear all
NCT05181605 2022-08-09

Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors

Instituto de investigación e innovación biomédica de Cádiz

Phase 2/3 Unknown
116 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡